Zoetis Inc. (NYSE:ZTS) Shares Purchased by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. boosted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 21.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 105,325 shares of the company's stock after purchasing an additional 18,318 shares during the period. Stock Yards Bank & Trust Co.'s holdings in Zoetis were worth $17,342,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Rakuten Securities Inc. increased its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC acquired a new stake in Zoetis during the fourth quarter valued at $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the fourth quarter valued at about $44,000. Asset Planning Inc bought a new position in Zoetis during the fourth quarter valued at about $58,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of Zoetis in the fourth quarter worth about $59,000. Institutional investors own 92.80% of the company's stock.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Zoetis Price Performance

ZTS traded down $4.55 during trading on Friday, hitting $164.27. 2,973,481 shares of the company traded hands, compared to its average volume of 2,551,305. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock's 50-day simple moving average is $158.67 and its two-hundred day simple moving average is $164.01. The company has a market cap of $73.13 billion, a PE ratio of 30.03, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the business posted $1.38 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of "Buy" and a consensus target price of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.